Joint Relationship of Cardiovascular-kidney-metabolic Syndrome and Psoriasis with All-cause and Cause-specific Mortality in Adults: A Population-based Analysis
DOI:
https://doi.org/10.2340/actadv.v106.adv-2025-0241Keywords:
cardiovascular-kidney-metabolic syndrome, psoriasis, mortality, epidemiology, NHANESAbstract
Psoriasis has been associated with cardiovascular risk, but the combined association of psoriasis and cardiovascular-kidney-metabolic (CKM) syndrome with mortality remains unclear. This study examined the individual and joint associations of CKM syndrome and self-reported psoriasis with allcause and cardio-cerebrovascular disease (CCD) mortality among 9,598 U.S. adults aged ≥20 years from NHANES 2003–2006 and 2009–2014. CKM syndrome stages were defined according to the 2023 American Heart Association framework, and psoriasis was assessed by self-reported physician diagnosis. Mortality was ascertained through linkage to the National Death Index through 2019. During a median follow-up of 9.3 years, 860 deaths occurred. Advanced CKM syndrome was associated with higher all-cause mortality (HR=3.67; 95% CI: 3.00–4.50) and CCD mortality (HR=8.16; 95% CI: 5.42–12.28). Psoriasis was also associated with higher all-cause mortality (HR=2.06; 95% CI: 1.47–2.90) and CCD mortality (HR=2.69; 95% CI: 1.42–5.08). Participants with both advanced CKM syndrome and psoriasis had the highest observed risks of all-cause mortality (HR=7.09; 95% CI: 4.93–10.19) and CCD mortality (HR=16.47; 95% CI: 7.26–37.33). Formal interaction testing did not show significant multi-plicative interaction for all-cause mortality (p for interaction=0.16) or CCD mortality (p for interaction=0.80). These findings suggest that coexisting advanced CKM syndrome and psoriasis may identify adults with particularly elevated mortality risk.
Downloads
References
Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol 2021; 157: 940–946. DOI: https://doi.org/10.1001/jamadermatol.2021.2007
Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 2020; 323: 1945–1960. DOI: https://doi.org/10.1001/jama.2020.4006
Masson W, Lobo M, Molinero G. Psoriasis and cardiovascular risk: a comprehensive review. Adv Ther 2020; 37: 2017–2033. DOI: https://doi.org/10.1007/s12325-020-01346-6
Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases. J Am
Acad Dermatol 2017; 76: 377–390. DOI: https://doi.org/10.1007/s00393-017-0317-1
Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-kidney-metabolic health: apresidential advisory from the American Heart Association. Circulation 2023; 148: 1606–1635. DOI: https://doi.org/10.1161/CIR.0000000000001184
Vollset SE, Ababneh HS, Abate YH, Abbafati C, Abbasgholizadeh R, Abbasian M, et al. Burden of disease
scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study
2021. Lancet 2024; 403: 2204–2256.
Tsai MK, Kao JTW, Wong CS, Liao CT, Lo WC, Chien KL, et al. Cardiovascular-kidney-metabolic syndrome and all-cause and
cardiovascular mortality: a retrospective cohort study. PLoS Med 2025; 22: e1004629. DOI: https://doi.org/10.1371/journal.pmed.1004629
Ostrominski JW, Arnold SV, Butler J, Fonarow GC, Hirsch JS, Palli SR, et al. Prevalence and overlap of cardiac, renal, and
metabolic conditions in US adults, 1999–2020. JAMA Cardiol 2023; 8: 1050–1060. DOI: https://doi.org/10.1001/jamacardio.2023.3241
McDonald CJ, Calabresi P. Thromboembolic disorders associated with psoriasis. Arch Dermatol 1973; 107: 918. DOI: https://doi.org/10.1001/archderm.1973.01620210078025
McDonald CJ, Calabresi P. Occlusive vascular disease in psoriatic patients. N Engl J Med 1973; 288: 912. DOI: https://doi.org/10.1056/NEJM197304262881715
Singh S, Young P, Armstrong AW. Relationship between psoriasis and metabolic syndrome: a systematic review. G Ital
Dermatol Venereol 2016; 151: 663–677.
Chan WMM, Yew YW, Theng TSC, Liew CF, Oon HH. Prevalence of metabolic syndrome in patients with psoriasis: a crosssectional
study in Singapore. smedj 2020; 61: 194–199.
Furue M, Tsuji G, Chiba T, Kadono T. Cardiovascular and metabolic diseases comorbid with psoriasis: beyond the skin.
Intern Med 2017; 56: 1613–1619. DOI: https://doi.org/10.2169/internalmedicine.56.8209
Picard D, Bénichou J, Sin C, Abasq C, Houivet E, Koning R, et al. Increased prevalence of psoriasis in patients with
coronary artery disease: results from a case–control study. Br J Dermatol 2014; 171: 580–587. DOI: https://doi.org/10.1111/bjd.13155
Pannu S, Rosmarin D. Psoriasis in patients with metabolic syndrome or type 2 diabetes mellitus: treatment challenges.
Am J Clin Dermatol 2021; 22: 293–300. DOI: https://doi.org/10.1007/s40257-021-00590-y
Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, et al. A synopsis of the evidence for the science and
clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart
Association. Circulation 2023; 148: 1636–1664.
Aggarwal R, Ostrominski JW, Vaduganathan M. Prevalence of cardiovascular-kidney-metabolic syndrome stages in US
adults, 2011–2020. JAMA 2024; 331: 1858–1860. DOI: https://doi.org/10.1001/jama.2024.6892
Zhu X, Cheang I, Fu Y, Chen S, Liang G, Yuan H, et al. Comparative discrimination of Life’s Simple 7, Life’s Essential
8, and Life’s Crucial 9: evaluating the impact of added complexity on mortality prediction. BMC Med 2025; 23: 265. DOI: https://doi.org/10.1186/s12916-025-04116-9
Li J, Wei X. Association of cardiovascular-kidney-metabolic syndrome with all-cause and cardiovascular mortality: a
prospective cohort study. Am J Prev Cardiol 2025; 22: 100985. DOI: https://doi.org/10.1016/j.ajpc.2025.100985
Zheng Q, Cao Z, Teng J, Lu Q, Huang P, Zhou J. Association between atherogenic index of plasma with all-cause and
cardiovascular mortality in individuals with Cardiovascular- Kidney-Metabolic syndrome. Cardiovasc Diabetol 2025; 24: DOI: https://doi.org/10.1186/s12933-025-02940-0
183.
Qiu Z, Chen X, Geng T, Wan Z, Lu Q, Li L, et al. Associations of serum carotenoids with risk of cardiovascular mortality
among individuals with type 2 diabetes: results from NHANES. Diabetes Care 2022; 45: 1453–1461. DOI: https://doi.org/10.2337/dc21-2371
Zhu X, Cheang I, Tang Y, Shi M, Zhu Q, Gao R, et al. Associations of serum carotenoids with risk of all-cause and
cardiovascular mortality in hypertensive adults. J Am Heart Assoc 2023; 12: e027568.
Patrick MT, Li Q, Wasikowski R, Mehta N, Gudjonsson JE, Elder JT, et al. Shared genetic risk factors and causal association
between psoriasis and coronary artery disease. Nat Commun 2022; 13: 6565.
Egeberg A, Skov L, Joshi AA, Mallbris L, Gislason GH, Wu JJ, et al. The relationship between duration of psoriasis, vascular
inflammation, and cardiovascular events. J Am Acad Dermatol 2017; 77: 650–656. DOI: https://doi.org/10.1016/j.jaad.2017.06.028
Kan J, Chen Q, Tao Q, Wu L, Wang D, Jiang Z, et al. Prospective evaluation of cardiovascular risk and mortality in
patients with psoriasis: an American population-based study. Exp Dermatol 2024; 33: e15010.
Dhana A, Yen H, Yen H, Cho E. All-cause and cause-specific mortality in psoriasis: a systematic review and meta-analysis.
J Am Acad Dermatol 2019; 80: 1332–1343. DOI: https://doi.org/10.1016/j.jaad.2018.12.037
Li N, Li Y, Cui L, Shu R, Song H, Wang J, et al. Association between different stages of cardiovascular-kidney-metabolic
syndrome and the risk of all-cause mortality. Atherosclerosis 2024; 397: 118585. DOI: https://doi.org/10.1016/j.atherosclerosis.2024.118585
Claudel SE, Schmidt IM, Waikar SS, Verma A. Cumulative incidence of mortality associated with cardiovascularkidney-
metabolic (CKM) syndrome. J Am Soc Nephrol 2025; 36: 1343–1351. DOI: https://doi.org/10.1681/ASN.0000000637
Zhao H, Wu J, Wu Q. Synergistic impact of psoriasis and hypertension on all-cause mortality risk: a prospective cohort
study. PLoS One 2024; 19: e0306048. DOI: https://doi.org/10.1371/journal.pone.0306048
Lu J, Li H, Wang S. Interaction effect of psoriasis and chronic kidney disease on the risk of all-cause mortality:
a prospective cohort study of NHANES data. Nephrol Dial Transplant 2023; 38: 2474–2484. DOI: https://doi.org/10.1093/ndt/gfad089
Kong X, Wang W. Synergistic effect of psoriasis and metabolic syndrome on risk of all-cause and cardiovascular mortality in US adults: a nationwide cohort study. Clin Exp Dermatol 2024; 50: 113–119. DOI: https://doi.org/10.1093/ced/llae340
Piaserico S, Orlando G, Messina F. Psoriasis and cardiometabolic diseases: shared genetic and molecular
pathways. Int J Mol Sci 2022; 23: 23. DOI: https://doi.org/10.3390/ijms232112949
Armstrong AW, Blauvelt A, Callis Duffin K, Huang YH, Savage LJ, Guo L, et al. Psoriasis. Nat Rev Dis Primers 2025; 11: 45. DOI: https://doi.org/10.1038/s41572-025-00630-5
Egeberg A, Gisondi P, Carrascosa JM, Warren RB, Mrowietz U. The role of the interleukin-23/Th17 pathway in
cardiometabolic comorbidity associated with psoriasis. J Eur Acad Dermatol Venereol 2020; 34: 1695–1706. DOI: https://doi.org/10.1111/jdv.16273
Pinter A, Schwarz P, Gerdes S, Simon JC, Saalbach A, Rush J, et al. Biologic treatment in combination with lifestyle
intervention in moderate to severe plaque psoriasis and concomitant metabolic syndrome: rationale and methodology
of the METABOLyx randomized controlled clinical trial. Nutrients 2021; 13: 3015. DOI: https://doi.org/10.3390/nu13093015
Flammer AJ, Ruschitzka F. Psoriasis and atherosclerosis: two plaques, one syndrome? Eur Heart J 2012; 33: 1989–1991. DOI: https://doi.org/10.1093/eurheartj/ehr425
Additional Files
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
